A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Laboratory Scale Production and Purification of a Therapeutic Antibody

17.5K views

⸱

DOI:

10.3791/55153

⸱

January 24th, 2017

 ,  ,  ,  , 

In This Article

Summary

This protocol describes the production of a therapeutic antibody in a mammalian expression system. The methods described include preparation of vector DNA, stable transfection and serum-free adaptation of a human embryonic kidney 293 cell line, set up of large scale cultures and purification using affinity chromatography.

Abstract

Ensuring the successful production of a therapeutic antibody begins early on in the development process. The first stage is vector expression of the antibody genes followed by stable transfection into a suitable cell line. The stable clones are subjected to screening in order to select those clones with desired production and growth characteristics. This is a critical albeit time-consuming step in the process. This protocol considers vector selection and sourcing of antibody sequences for the expression of a therapeutic antibody. The methods describe preparation of vector DNA for stable transfection of a suspension variant of human embryonic kidney 293 (HEK-293) cell line, using polyethylenimine (PEI). The cells are transfected as adherent cells in serum-containing media to maximize transfection efficiency, and afterwards adapted to serum-free conditions. Large scale production, setup as batch overgrow cultures is used to yield antibody protein that is purified by affinity chromatography using an automated fast protein liquid chromatography (FPLC) instrument. The antibody yields produced by this method can provide sufficient protein to begin initial characterization of the antibody. This may include in vitro assay development or physicochemical characterization to aid in the time-consuming task of clonal screening for lead candidates. This method can be transferable to the development of an expression system for the production of biosimilar antibodies.

Introduction

The success of therapeutic antibodies continues to drive substantial investment into antibody development as a wave of next generation therapeutics begins. The antibody market is expected to be reshaped by antibody fragments 1, antibody-drug conjugates 2, bispecific antibodies 3 and engineered antibodies with favorable properties 4. Another class gaining pharmaceutical interest are biosimilars. Biosimilar antibodies are 'highly similar' replicate products of a therapeutic antibody that has already received regulatory approval. A proposed biosimilar must be comparabl....

Access restricted. Please log in or start a trial to view this content.

Protocol

NOTE: A suitable mammalian expression vector must be used for this protocol. Here, a single construct containing two expression cassettes is used (i.e. heavy and light chain expression is driven by separate promoters). Trastuzumab heavy and light chains were previously cloned into the vector. This vector was a gift from Andrew Beavil, obtained through a not-for-profit plasmid repository 13.

1. Recovery and Scale-up of Vector DNA

NOTE: Vector DNA was received as a soft agar stab culture in Escherichia coli XL-1 Blue strain; vector carries hygromycin resistance.

  1. Insert a sterile inoculation stab or loop....

Access restricted. Please log in or start a trial to view this content.

Results

Stable production of trastuzumab by transfected HEK-293 cells was confirmed using bio-layer interferometry (BLI) as presented in Figure 1. An IgG standard curve was generated by measuring the binding rate between an IgG antibody standard and Protein A biosensor (Figure 1A). The crude supernatant sample was similarly measured, then its concentration interpolated from the standard curve (Figure 1B). The supernatant concentration was measure.......

Access restricted. Please log in or start a trial to view this content.

Discussion

This protocol details the transfection, stable expression and purification of a therapeutic antibody in HEK-293 cells. Stable expression of antibody genes is the first step in generating an antibody-producing cell line for the development and manufacture of a therapeutic antibody. While Chinese hamster ovary (CHO) cells remain the expression platform of choice for therapeutic proteins, the HEK-293 cell line is gaining prominence with the realization that proteins produced in these cells are a closer match to naturally oc.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

The research was supported by the University of Sydney. pVITRO1-Trastuzumab-IgG1/κ was a gift from Andrew Beavil (Addgene plasmid # 61883). We thank Tihomir S. Dodev for useful discussions regarding pVITRO1-Trastuzumab-IgG1/κ.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
pFUSE vector seriesInvivoGenN/AHeavy and light antibody genes expressed in separate vectors that require co-transfection.
mAbXpress vector seriesACYTE Biotech Pty Ltd.Heavy and light antibody genes expressed in separate vectors that require co-transfection. Refer to: Jones, M. L. et al. A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies. J Immunol Methods. 354 (1-2), 85-90, doi:10.1016/j.jim.2010.02.001, (2010).
pVITRO1 vectorN/AN/AHeavy and light antibody genes are each driven by a separate promoter in a single vector.  Refer to: Dodev, T. S. et al. A tool kit for rapid cloning and expression of recombinant antibodies. Sci Rep. 4 5885, doi:10.1038/srep05885, (2014).
GS vector seriesLonzaMulti-cistronic vector with heavy and light antibody genes co-expressed and translated as single transcript.
Multi-cistronic vector series 1N/AN/AMulti-cistronic vector with heavy and light antibody genes co-expressed and translated as single transcript. Refer to: Li, J. et al. A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies. J Immunol Methods. 318 (1-2), 113-124, doi:10.1016/j.jim.2006.10.010, (2007).
Multi-cistronic vector series 2N/AN/AMulti-cistronic vector with heavy and light antibody genes co-expressed and translated as single transcript. Refer to: Ho, S. C. et al. IRES-mediated Tricistronic vectors for enhancing generation of high monoclonal antibody expressing CHO cell lines. J Biotechnol. 157 (1), 130-139, doi:10.1016/j.jbiotec.2011.09.023, (2012).
pVITRO1-Trastuzumab-IgG1/κAddgene61883Mammalian expression vector containing trastuzumab antibody genes with hygromycin resistance gene; pVITRO1-Trastuzumab-IgG1/κ was a gift from Andrew Beavil.
Fast-Media Hygro AgarJomar Life Researchfas-hg-sUsed to prepare low salt LB agar containing 75 µg/ml hygromycin.
Fast-Media Hygro TBJomar Life Researchfas-hg-lUsed to prepare low salt TB broth containing 75 µg/ml hygromycin. 
Glycerol, BioXtra, ≥99%Sigma-AldrichG6279Prepare to 80% with water and autoclave. Store at room temperature.
Jestar 2.0/LFU Plasmid Maxi KitAstral ScientificG221020Plasmid Maxi Prep Kit; elute or resuspend DNA in water (pH 7.0-8.5).
FreeStyle 293-F CellsLife TechnologiesR790-07HEK-293 cell line adapted to suspension culture in serum-free media.
FreeStyle 293 Expression MediumLife Technologies12338-018Serum-free media specially formulated for maintaing 293-F cell line and high protein expression.
Kolliphor P188Sigma-AldrichK4894Non-ionic surfactant; pluronic F-68; prepare to 10% in water and filter-sterilize using 0.22 μm filter. Store at 4 °C.
DMEM, high glucose Life Technologies11995-065
Heat-Inactivated Foetal Bovine SerumLife Technologies10082-147
Polyethylenimine, Linear, MW 25,000 Polysciences, Inc.23966Prepare to 1 mg/ml in water. Adjust to pH 7.0 with 1 M HCl (solution becomes clear) and filter-sterilize using 0.22 μm filter. Store at -80 °C until use.
OptiPro SFMLife Technologies12309-050Transfection formulated serum-free media
Hygromycin B SolutionJomar Life Researchant-hg-1
Dimethylsulphoxide (DMSO)Thermo Fisher ScientificAJA2225
Tryptone (casein peptone)Thermo Fisher ScientificLP0042BPrepare to 20% in PBS and filter-sterilize using 0.22 μm filter. Store at 4 °C. 
Phosphate Buffered Saline (PBS) Tablets, pH 7.4, 100 mlAstral Scientific09-2051-100
HiTrap Protein A High Performance, 1 x 5 ml columnSigma-AldrichGE17-0403-01
AKTApurifier 100GE Healthcare28406266Automated FPLC system, which can include a P-960 sample pump and Frac-920 fraction collector.
Glycine-HClSigma-AldrichG2879
Citric Acid, monohydrateAstral ScientificBIOC2123
Sodium Citrate, trisodium salt dihydrate Astral ScientificBIOCB0035
1 M Tris-HCl solution pH 9.0Astral ScientificBIOSD8146
Amicon Ultra Centrifugal Filters (30 MWCO)Merck MilliporeUFC803008/UFC903008Used to buffer exchange and concentrate purified protein.
Pierce Bicinchoninic Acid (BCA) Assay KitThermo Fisher Scientific23227
BLItz SystemfortéBIO45-5000Instrument used for bio-layer interferometry (BLI) measurements.
Protein A biosensorsfortéBIO18-5010
Acrylamide/Bisacrylamide (37.5:1), 40% solutionAstral Scientific786-502
Ammonium Persulfate (APS)Astral ScientificAM0486
TEMEDAstral ScientificAM0761
Coomassie Brilliant Blue R-250Astral Scientific786-498
Precision Plus Dual-Color Protein StandardBio-Rad1610374

References

  1. Nelson, A. L., Reichert, J. M. Development trends for therapeutic antibody fragments. Nat Biotechnol. 27 (4), 331-337 (2009).
  2. Drake, P. M., Rabuka, D. An emerging playbook for antibody-drug conjugates: lessons f....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Therapeutic Antibody ProductionHEK-293 Cell LineStable TransfectionPolyethylenimine TransfectionSerum-Free AdaptationAffinity ChromatographyFPLC PurificationAntibody Yield MeasurementBuffer ExchangeBiolayer Interferometry